Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases

被引:86
作者
Mueller, Thomas [1 ]
Leitner, Isabella [1 ]
Egger, Margot [1 ]
Haltmayer, Meinhard [1 ]
Dieplinger, Benjamin [1 ]
机构
[1] Konventhosp Barmherzige Brueder, Dept Lab Med, A-4020 Linz, Austria
关键词
Cardiac troponin; Galectins; Inflammation; Interleukin-1 receptor family; Natriuretic peptides; Transforming growth factor beta superfamily; INHIBITORY CYTOKINE-1; AMERICAN-COLLEGE; GUIDELINES; MANAGEMENT; COMMUNITY; DEFINITIONS; PNEUMONIA; DIAGNOSIS; MEDICINE; SEPSIS;
D O I
10.1016/j.cca.2015.03.033
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: The biomarkers soluble ST2 (5ST2), galectin-3, and growth-differentiation factor-15 (GDF-15) provide prognostic information in patients with heart failure (HF). The aim of this study was to evaluate to which extent plasma concentrations of these biomarkers are increased in HF compared with diverse non-cardiac conditions such as infectious disease or chronic kidney disease. Methods: We recruited 15 patients in each of the following clinical categories: HF without co-morbidity, pneumonia without co-morbidity, chronic obstructive pulmonary disease (COPD) without co-morbidity, HF and a co-morbidity of pneumonia, renal disease without co-morbidity, and sepsis. We used 22 healthy individuals as control group. In each of the 112 study participants, we measured plasma concentrations of sST2 (Presage assay), galecfin-3 (Abbott assay) and GDF-15 (Roche assay). Results: Compared to controls, the median sST2 concentration was similar to 2.5-fold increased in HF, similar to 3.5-fold in pneumonia, similar to 5.0-fold in COPD, similar to 5.8-fold in HF + pneumonia, and similar to 70-fold in sepsis (p < 0.001 for all). sST2 was not significantly increased in renal disease. Compared to controls, the median galectin-3 concentration was similar to 1.5-fold increased in HF, similar to 1.4-fold in pneumonia, similar to 2.4-fold in HF + pneumonia, similar to 25-fold in renal disease, and similar to 2.7-fold in sepsis (p < 0.001 for all). Galectin-3 was not significantly increased in COPD. Compared to controls, the median GDF-15 concentration was similar to 4.4-fold increased in HF, similar to 5.4-fold in pneumonia, similar to 2.1-fold in COPD, similar to 83-fold in HF + pneumonia, similar to 5.1-fold in renal disease, and similar to 27-fold in sepsis (p < 0.001). In the 112 study participants, correlation analyses revealed a relatively strong association between galectin-3 and GDF-15 (correlation coefficient, 0.739; p < 0.001). Conclusion: Because increased plasma concentrations of sST2, galectin-3, and GDF-15 are not specific for a distinct disease group, the three biomarkers are not useful for diagnostic purposes. The results of our study are novel with respect to sST2, galectin-3 and GDF-15 as markers of inflammatory diseases and should encourage further studies. (C) 2015 The Authors. Published by Elsevier B.V.
引用
收藏
页码:155 / 160
页数:6
相关论文
共 31 条
[1]   Prognostic value of troponins in sepsis: a meta-analysis [J].
Bessiere, Francis ;
Khenifer, Safia ;
Dubourg, Julie ;
Durieu, Isabelle ;
Lega, Jean-Christophe .
INTENSIVE CARE MEDICINE, 2013, 39 (07) :1181-1189
[2]   AMERICAN-COLLEGE OF CHEST PHYSICIANS SOCIETY OF CRITICAL CARE MEDICINE CONSENSUS CONFERENCE - DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ ;
ABRAMS, JH ;
BERNARD, GR ;
BIONDI, JW ;
CALVIN, JE ;
DEMLING, R ;
FAHEY, PJ ;
FISHER, CJ ;
FRANKLIN, C ;
GORELICK, KJ ;
KELLEY, MA ;
MAKI, DG ;
MARSHALL, JC ;
MERRILL, WW ;
PRIBBLE, JP ;
RACKOW, EC ;
RODELL, TC ;
SHEAGREN, JN ;
SILVER, M ;
SPRUNG, CL ;
STRAUBE, RC ;
TOBIN, MJ ;
TRENHOLME, GM ;
WAGNER, DP ;
WEBB, CD ;
WHERRY, JC ;
WIEDEMANN, HP ;
WORTEL, CH .
CRITICAL CARE MEDICINE, 1992, 20 (06) :864-874
[3]   COPD exacerbations: definitions and classifications [J].
Burge, S ;
Wedzicha, JA .
EUROPEAN RESPIRATORY JOURNAL, 2003, 21 :46S-53S
[4]   Concise Review: Growth Differentiation Factor 15 in Pathology: A Clinical Role? [J].
Corre, Jill ;
Hebraud, Benjamin ;
Bourin, Philippe .
STEM CELLS TRANSLATIONAL MEDICINE, 2013, 2 (12) :946-952
[5]   Soluble ST2 in heart failure [J].
Dieplinger, Benjamin ;
Mueller, Thomas .
CLINICA CHIMICA ACTA, 2015, 443 :57-70
[6]   Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department [J].
Dieplinger, Benjamin ;
Gegenhuber, Alfons ;
Kaar, Gerhard ;
Poelz, Werner ;
Haltmayer, Meinhard ;
Mueller, Thomas .
CLINICAL BIOCHEMISTRY, 2010, 43 (09) :714-719
[7]   Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma - The Presage™ ST2 assay [J].
Dieplinger, Benjamin ;
Januzzi, James L., Jr. ;
Steinmair, Martin ;
Gabriel, Christian ;
Poelz, Werner ;
Haltmayer, Meinhard ;
Mueller, Thomas .
CLINICA CHIMICA ACTA, 2009, 409 (1-2) :33-40
[8]   Biomarkers and diagnostics in heart failure [J].
Gaggin, Hanna K. ;
Januzzi, James L., Jr. .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2013, 1832 (12) :2442-2450
[9]   Galectin-3: its role in asthma and potential as an anti-inflammatory target [J].
Gao, Peng ;
Simpson, Jodie L. ;
Zhang, Jie ;
Gibson, Peter G. .
RESPIRATORY RESEARCH, 2013, 14
[10]   The regulation of inflammation by galectin-3 [J].
Henderson, Neil C. ;
Sethi, Tariq .
IMMUNOLOGICAL REVIEWS, 2009, 230 :160-171